

GENITOURINARY CLINICAL TRIALS

BLADDER

BMS CA209901

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

A031501

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Lo-cally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

S1602

A Phase III randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer.

RENAL CELL CARCINOMA

BTCRC-GU16-043

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

PROSTATE

NRG GU006

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Antiandrogen Therapy with Apalutamide in Recurrent Prostate Cancer

ProSTAR

A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

S1802

“Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer)

GERM CELL TUMORS

A031102

A Randomized Phase III Trial comparing conventional-dose chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy using Mobilizing Paclitaxel plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors

AGCT1521

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatrics and Adult patients with Germ Cell Tumors

